The Department of Health and Human Services will partner with more than a dozen biopharmaceutical companies and the European Medicines Agency to prioritize vaccine and drug candidates, streamline clinical trials and coordinate regulatory processes to respond to the pandemic, the National Institutes of Health announced today.

“We need to bring the full power of the biomedical research enterprise to bear on this crisis,” said NIH Director Francis Collins, M.D. “Now is the time to come together with unassailable objectivity to swiftly advance the development of the most promising vaccine and therapeutic candidates that can help end the COVID-19 global pandemic.”

In addition to NIH, HHS participants in the Accelerating COVID-19 Therapeutic Interventions and Vaccines partnership include the Office of the Assistant Secretary for Preparedness and Response, Centers for Disease Control and Prevention and Food and Drug Administration.

Related News Articles

Headline
Adults age 65 and older are encouraged to receive an updated dosage of the COVID-19 vaccine, the Centers for Disease Control and Prevention announced April 25…
Headline
The Pfizer and Moderna COVID-19 vaccines can cause myocarditis, but do not appear to cause infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with…
Headline
The Food and Drug Administration recently granted emergency use authorization for the first over-the-counter home antigen test to detect both flu and COVID-19…
Headline
Centers for Disease Control and Prevention Director Mandy Cohen, M.D., Feb. 28 endorsed a recommendation by its Advisory Committee on Immunization Practices…
Headline
Paxlovid may no longer be distributed with an emergency use label after March 8, the Food and Drug Administration announced. Providers may dispense unexpired…
Headline
A CDC study  released Dec. 21 found low COVID-19 and flu vaccination coverage for most adults, and low RSV vaccination coverage for adults aged 60 and…